Sugi Predict

Sugi Predict / Compounds / SCHEMBL2187189

SCHEMBL2187189

SCHEMBL2187189

CC(C)(C)OC(=O)Nc1ccc(C(=O)O)c(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.54
▸ PKM P14618 1/20 0.54
▸ HSD17B10 Q99714 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ MAPT P10636 2/20 0.50
▸ CYP2D6 P10635 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ ATM Q13315 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CA12 O43570 2/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ STAT3 P40763 1/20 0.46
▸ CTDSP1 Q9GZU7 1/20 0.46
▸ SIRT5 Q9NXA8 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338918 1.00 KMT2A (0.54) KMT2APKMHSD17B10KDM4EMAPT
SCHEMBL596681 0.88 KDM4E (0.64) KMT2APKMHSD17B10KDM4EMAPT
SCHEMBL30339301 0.88 KDM4E (0.64) KMT2APKMHSD17B10KDM4EMAPT
SCHEMBL16412251 0.88 KDM4E (0.49) KMT2AHSD17B10KDM4EMAPTCYP2D6
SCHEMBL9081119 0.87 SMN1; SMN2 (0.66) HSD17B10KDM4EMAPTCYP2D6POLB
SCHEMBL509152 0.85 CA12 (0.53) KMT2AHSD17B10KDM4EMAPTCYP2D6
SCHEMBL7454764 0.84 KMT2A (0.59) KMT2APKMHSD17B10KDM4EMAPT
SCHEMBL28423282 0.84 CA12 (0.51) KMT2AHSD17B10KDM4EMAPTCYP2D6
SCHEMBL15753831 0.84 RARA (0.46) KMT2AHSD17B10KDM4EMAPTCYP2D6
SCHEMBL4697609 0.84 CA12 (0.46) KMT2AHSD17B10KDM4EMAPTCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 — — US disclosed
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 — — US disclosed
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 — — US disclosed
CN-116472292-A Modified proteins and protein degrading agents 上海睿跃生物科技有限公司 2023-07-21 — — CN disclosed
US-20230057177-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2023-02-23 — — US disclosed
US-20230057177-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2023-02-23 — — US disclosed
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors UNIVERSITY OF HAWAII (US) 2022-04-12 — — US disclosed
CN-111356456-A 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor 夏威夷大学 2020-06-30 — — CN disclosed
EP-2542529-B1 URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA LLC PHARMADIALL (RU) 2019-09-04 — — EP disclosed
WO-2018136935-A1 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS UNIVERSITY OF HAWAII (US) 2018-07-26 — — WO disclosed
US-20060211728-A1 Thalidomide analogs P2D INC. 2006-09-21 — — US disclosed
EP-1663223-A2 THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2006-06-07 — — EP disclosed
WO-2005028436-A2 THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-03-31 — — WO disclosed
US-6710056-B2 PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. AJINOMOTO CO., INC. (JP) 2004-03-23 — — US disclosed
US-20030109547-A1 Amidinophenylpyruvic acid derivatives AJINOMOTO CO. INC (JP) 2003-06-12 — — US disclosed
EP-1236712-A1 AMIDINOPHENYLPYRUVIC ACID DERIVATIVE Ajinomoto Co., Inc. (JP) 2002-09-04 — — EP disclosed
EP-0837070-B1 SIALIC ACID DERIVATIVES MITSUBISHI CHEM CORP (JP) 2001-10-31 — — EP disclosed
US-6288041-B1 Sialic acid derivatives MITSUBISHI CHEMICAL CORPORATION (JP) 2001-09-11 — — US disclosed
EP-0837070-A1 SIALIC ACID DERIVATIVES MITSUBISHI CHEMICAL CORPORATION (JP) 1998-04-22 — — EP disclosed
WO-1996034851-A1 BENZENE, PYRIDINE, NAPHTALENE OR BENZOPHENONE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE ABBOTT LABORATORIES (US) 1996-11-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors STAT3, JAK2, STAT5A KMT2A 510/4885PKM 3814/4885HSD17B10 2929/4885
US-20060211728-A1 Thalidomide analogs TNF, TNFRSF1A, PGF KMT2A 3148/4885PKM 4765/4885HSD17B10 4209/4885
US-20030109547-A1 Amidinophenylpyruvic acid derivatives HABP2, F2, F7 KMT2A 3854/4885PKM 175/4885HSD17B10 1277/4885
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, MDM2 KMT2A 1342/4885PKM 2487/4885HSD17B10 2241/4885
US-20230057177-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, MDM2 KMT2A 1342/4885PKM 2487/4885HSD17B10 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.